1.
Ugeskr Laeger
; 186(4)2024 01 22.
Article
in Danish
| MEDLINE
| ID: mdl-38305321
ABSTRACT
During the last two decades, novel targeted therapies, in particular, ¼small molecules« for oral administration and monoclonal antibodies, have revolutionized the treatment and prognosis of haematological cancers. Generally, these treatments are well tolerated and therefore suitable for elderly patients. This review presents a short update on the current standard-of-care treatment of elderly patients with haematological cancer.